日中の過度の眠気（EDS）- 市場洞察、疫学、市場予測：2032年

主要7ヶ国における日中の過度の眠気（EDS）治療の市場規模は、2021年に49億4,600万米ドルとなりました。同市場は今後、6.77％のCAGRで拡大すると予測されています。

当レポートでは、主要7ヶ国における日中の過度の眠気（EDS）市場について調査し、市場の概要とともに、疫学と患者動向、医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 日中の過度の眠気（EDS）市場概要

第4章 日中の過度の眠気（EDS）市場：将来の展望

第5章 日中の過度の眠気（EDS）市場のエグゼクティブサマリー

第6章 主要なイベント

第7章 日中の過度の眠気（EDS）：病気の背景と概要

• イントロダクション
• 原因
• 症状
• 分類
• 診断
• 治療と管理

第8章 疫学と患者人口

• 主な調査結果
• 疫学調査手法
• 仮定と理論的根拠：主要7ヶ国
  • 米国
  • 欧州主要5ヶ国（ドイツ、フランス、イタリア、スペイン、英国）
  • 日本
• 主要7ヶ国における診断済患者人口
• 米国
• 欧州主要5ヶ国（ドイツ、フランス、イタリア、スペイン、英国）
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本

第9章 患者動向

第10章 市販薬

第11章 新薬

第12章 日中の過度の眠気（EDS）：主要7ヶ国市場分析

• 主な調査結果
• 市場調査手法
• 主要7ヶ国における日中の過度の眠気（EDS）市場規模
• 主要7ヶ国の日中の過度の眠気（EDS）市場規模、治療別
• 現在および新たな治療法の可能性
• 主要な市場予測の前提条件
• 属性分析
• 市場の見通し
• 米国における日中の過度の眠気（EDS）市場規模
• 欧州主要5ヶ国における日中の過度の眠気（EDS）市場規模
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本における日中の過度の眠気（EDS）市場規模

第13章 キーオピニオンリーダーの見解

第14章 市場促進要因

第15章 市場阻害要因

第16章 SWOT分析

第17章 アンメットニーズ

第18章 償還と市場アクセス

第19章 付録

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

List of Tables

• Table 1 Summary of Excessive Daytime Sleepiness Market and Epidemiology (2019-2032)
• Table 2 Key Events
• Table 3 Common Causes or Contributors to Excessive Daytime Sleepiness
• Table 4 ESS Scores
• Table 5 Diagnostic Criteria for Narcolepsy Types 1 and 2 (Adapted from ICSD-3)
• Table 6 Diagnostic Criteria for Idiopathic Hypersomnia (adapted from ICSD-3)
• Table 7 Current Pharmacologic Treatment of Excessive Daytime Sleepiness Associated with Narcolepsy
• Table 8 American Academy of Sleep Medicine Clinical Practice Guideline for the Treatment of Central Disorders of Hypersomnolence (1/3)
• Table 9 American Academy of Sleep Medicine Clinical Practice Guideline for the Treatment of Central Disorders of Hypersomnolence (2/3)
• Table 10 American Academy of Sleep Medicine Clinical Practice Guideline for the Treatment of Central Disorders of Hypersomnolence (3/3)
• Table 11 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the 7MM, in '000' (2019-2032)
• Table 12
• Table 13 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the US, in '000' (2019-2032)
• Table 14 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the US, in '000' (2019-2032)
• Table 15 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in EU-5, in '000' (2019-2032)
• Table 16 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in EU-5, in '000' (2019-2032)
• Table 17 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Germany, in '000' (2019-2032)
• Table 18 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Germany, in '000' (2019-2032)
• Table 19 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in France, in '000' (2019-2032)
• Table 20 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in France, in '000' (2019-2032)
• Table 21 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Italy, in '000' (2019-2032)
• Table 22 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Italy, in '000' (2019-2032)
• Table 23 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Spain, in '000' (2019-2032)
• Table 24 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Spain, in '000' (2019-2032)
• Table 25 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the UK, in '000' (2019-2032)
• Table 26 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the UK, in '000' (2019-2032)
• Table 27 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Japan, in '000' (2019-2032)
• Table 28 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the Japan, in '000' (2019-2032)
• Table 29 Comparison of Marketed Drugs Under Development
• Table 30 Wakix (Pitolisant), Clinical Trial Description, 2022 (1/3)
• Table 31 Wakix (Pitolisant), Clinical Trial Description, 2022 (2/3)
• Table 32 Wakix (Pitolisant), Clinical Trial Description, 2022 (3/3)
• Table 33 Highlights of Clinical trials
• Table 34 Sunosi, Clinical Trial Description, 2022 (1/2)
• Table 35 Sunosi, Clinical Trial Description, 2022 (2/2)
• Table 36 Efficacy Results for Maintenance of Wakefulness Test (minutes) in Patients With Narcolepsy (Study 1) and OSA (Study 2)
• Table 37 Efficacy Results for Epworth Sleepiness Scale in Patients With Narcolepsy (Study 1) and OSA (Study 2)
• Table 38 Efficacy Results from Randomized Withdrawal Studies in Patients With Narcolepsy and OSA in Studies 3 and 4
• Table 39 Xyrem, Clinical Trial Description, 2022
• Table 40 Median Number of Cataplexy Attacks in Trials N1 and N2
• Table 41 Change from Baseline in Daytime Sleepiness Score (Epworth Sleepiness Scale) at Week 8 in Trial N3 (Range 0-24)
• Table 42 The Proportion of Patients with a Very Much or Much Improved Clinical Global Impression of Change in Daytime and Nighttime Symptoms in Trial N3
• Table 43 Change in Baseline in the Maintenance of Wakefulness Test Score (in minutes) at Week 8 in Trial N4
• Table 44 Number of Weekly Cataplexy Attacks and Epworth Sleepiness Scale (Child and Adolescent) Score (Trial N5)
• Table 45 Clinical Global Impression of Change (CGIc) for Cataplexy Severity and Narcolepsy Overall (Trial N5)
• Table 46 Xywav, Clinical Trial Description, 2022
• Table 47 Mean and Median Number of Weekly Cataplexy Attacks and Epworth Sleepiness Scale (ESS)
• Table 48 Number of Weekly Cataplexy Attacks and Epworth Sleepiness Scale (Child and Adolescent) Score
• Table 49 Clinical Global Impression of Change (CGIc) for Cataplexy Severity and Narcolepsy Overall
• Table 50 Comparison of Emerging Drugs Under Development (1/3)
• Table 51 Comparison of Emerging Drugs Under Development (2/3)
• Table 52 Comparison of Emerging Drugs Under Development (3/3)
• Table 53 FT218, Clinical Trial Description, 2022
• Table 54 AXS-12, Clinical Trial Description, 2022
• Table 55 THN102, Clinical Trial Description, 2022
• Table 56 Samelisant, Clinical Trial Description, 2022
• Table 57 Quilience, Clinical Trial Description, 2022
• Table 58 XW10172, Clinical Trial Description, 2022
• Table 59 TAK-994 , Clinical Trial Description, 2022
• Table 60 Market Size of Excessive Daytime Sleepiness in the 7MM, in USD Million (2019-2032)
• Table 61 Market Size of Excessive Daytime Sleepiness by Therapies in the 7MM, in USD Million (2019-2032)
• Table 62 Key Market Forecast Assumptions for FT218 (for EDS in Narcolepsy)
• Table 63 Key Market Forecast Assumptions for Xywav (for EDS in Narcolepsy)
• Table 64 Key Market Forecast Assumptions for AXS-12 (for EDS in Narcolepsy)
• Table 65 Key Market Forecast Assumptions for Ozawade (for EDS in obstructive sleep apneoa)
• Table 66 Key Market Forecast Assumptions for Xywav (for EDS in Idiopathic Hypersomnia)
• Table 67 Key Market Forecast Assumptions for THN102 (for EDS in Parkinson's disease)
• Table 68 The United States Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Table 69 Market Size of Excessive Daytime Sleepiness by Therapies in the US, in USD Million (2019-2032)
• Table 70 EU-5 Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Table 71 EU-5 Market Size of Excessive Daytime Sleepiness by Therapies, in USD Million (2019-2032)
• Table 72 Germany Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Table 73 Market Size of Excessive Daytime Sleepiness by Therapies in Germany, in USD Million (2019-2032)
• Table 74 France Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Table 75 Market Size of Excessive Daytime Sleepiness by Therapies in France, in USD Million (2019-2032)
• Table 76 Italy Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Table 77 Market Size of Excessive Daytime Sleepiness by Therapies in Italy, in USD Million (2019-2032)
• Table 78 Spain Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Table 79 Market Size of Excessive Daytime Sleepiness by Therapies in Spain, in USD Million (2019-2032)
• Table 80 The United Kingdom Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Table 81 Market Size of Excessive Daytime Sleepiness by Therapies in the UK, in USD Million (2019-2032)
• Table 82 Market Size of Excessive Daytime Sleepiness in Japan, in USD Million (2019-2032)

List of Figures

• Figure 1 How EDS is Different from Fatigue?
• Figure 2 Causes of Excessive Daytime Sleepiness
• Figure 3 Symptoms of Excessive Daytime Sleepiness
• Figure 4 Suggested Clinical Algorithm for the Diagnosis of Suspected OSA, Narcolepsy, or Other Sleep Disorders Based on Symptoms of Excessive Daytime Sleepiness
• Figure 5 Clinical Approach in the Diagnosis of Excessive Daytime Sleepiness
• Figure 6 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the 7MM, in '000' (2019-2032)
• Figure 7 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the US, in '000' (2019-2032)
• Figure 8 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the US, in '000' (2019-2032)
• Figure 9 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in EU-5, in '000' (2019-2032)
• Figure 10 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in EU-5, in '000' (2019-2032)
• Figure 11 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Germany, in '000' (2019-2032)
• Figure 12 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Germany, in '000' (2019-2032)
• Figure 13 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in France, in '000' (2019-2032)
• Figure 14 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in France, in '000' (2019-2032)
• Figure 15 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Italy, in '000' (2019-2032)
• Figure 16 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Italy, in '000' (2019-2032)
• Figure 17 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Spain, in '000' (2019-2032)
• Figure 18 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Spain, in '000' (2019-2032)
• Figure 19 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the UK, in '000' (2019-2032)
• Figure 20 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the UK, in '000' (2019-2032)
• Figure 21 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Japan, in '000' (2019-2032)
• Figure 22 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the Japan, in '000' (2019-2032)
• Figure 23 Diagnostic and Treatment Approach for Excessive Daytime Sleepiness
• Figure 24 Market Size of Excessive Daytime Sleepiness in the 7MM, in USD Million (2019-2032)
• Figure 25 Market Size of Excessive Daytime Sleepiness by Therapies in the 7MM, in USD Million (2019-2032)
• Figure 26 Key Market Forecast Assumptions for FT218 (for EDS in Narcolepsy)
• Figure 27 Key Market Forecast Assumptions for Xywav (for EDS in Narcolepsy)
• Figure 28 Key Market Forecast Assumptions for AXS-12 (for EDS in Narcolepsy)
• Figure 29 Key Market Forecast Assumptions for Ozawade (for EDS in obstructive sleep apneoa)
• Figure 30 Key Market Forecast Assumptions for Xywav (for EDS in Idiopathic Hypersomnia)
• Figure 31 Key Market Forecast Assumptions for THN102 (for EDS in Parkinson's disease)
• Figure 32 The United States Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Figure 33 Market Size of Excessive Daytime Sleepiness by Therapies in the US, in USD Million (2019-2032)
• Figure 34 EU-5 Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Figure 35 EU-5 Market Size of Excessive Daytime Sleepiness by Therapies, in USD Million (2019-2032)
• Figure 36 Germany Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Figure 37 Market Size of Excessive Daytime Sleepiness by Therapies in Germany, in USD Million (2019-2032)
• Figure 38 France Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Figure 39 Market Size of Excessive Daytime Sleepiness by Therapies in France, in USD Million (2019-2032)
• Figure 40 Italy Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Figure 41 Market Size of Excessive Daytime Sleepiness by Therapies in Italy, in USD Million (2019-2032)
• Figure 42 Spain Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Figure 43 Market Size of Excessive Daytime Sleepiness by Therapies in Spain, in USD Million (2019-2032)
• Figure 44 The United Kingdom Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
• Figure 45 Market Size of Excessive Daytime Sleepiness by Therapies in the UK, in USD Million (2019-2032)
• Figure 46 Market Size of Excessive Daytime Sleepiness in Japan, in USD Million (2019-2032)
• Figure 47 Market Size of Excessive Daytime Sleepiness by Therapies in Japan, in USD Million (2019-2032)
• Figure 48 Market Drivers
• Figure 49 Market Barriers
• Figure 50 SWOT Analysis
• Figure 51 Unmet Needs

DelveInsight's 'Excessive Daytime Sleepiness-Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Excessive Daytime Sleepiness, historical and forecasted epidemiology as well as the Excessive Daytime Sleepiness market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Excessive Daytime Sleepiness market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Excessive Daytime Sleepiness market size from 2019 to 2032. The Report also covers current Excessive Daytime Sleepiness treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Excessive Daytime Sleepiness Disease Understanding and Treatment Algorithm

Excessive Daytime Sleepiness Overview

Excessive Daytime Sleepiness is characterized by a difficulty to stay awake and alert during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times of the wake period. Excessive Daytime Sleepiness is often associated with a wide range of illnesses, including metabolic, cardiovascular, neurological, and psychiatric diseases with voluntary behaviors reflecting poor sleep and sleep debt, leading to disability and increased risk of mortality. Excessive Daytime Sleepiness is also commonly associated with social and economic consequences, thus constituting a significant public health problem.

Sleep plays a vital role in consolidating memory, restoring the immune system, and other vital processes. As a result, a lack of quality sleep may result in a host of symptoms that may not immediately connect to sleep.

Continued in the report…..

Excessive Daytime Sleepiness Diagnosis

If an individual constantly feels drowsy during the day and tends to fall asleep at an awkward time and places that affect the productivity of the individual, then that individual needs to consult with a treating physician and discuss the situation. The physician will inquire about the sleeping habits of the patient. The physician will also inquire about any history of alcohol or drug use or abuse currently or in the past. The individual may also be referred to a psychologist for a counseling session if the individual has some stress or emotional problem in life, which could be interfering with sleep. The physician may also order tests to know about the exact cause of Excessive Daytime Sleepiness.

Sleep studies, such as the polysomnogram (PSG), the multiple sleep latency tests (MSLT), and the maintenance of wakefulness test (MWT), must be performed in a sleep laboratory, and although more labor-intensive, may also help evaluate diminished alertness and excessive sleepiness

Continued in the report…..

Excessive Daytime Sleepiness Treatment

The treatment of Excessive Daytime Sleepiness includes nonpharmacological and pharmacological treatment options. The management of Excessive Daytime Sleepiness depends on the underlying condition. Addressing the underlying cause is the mainstay of treatment of excessive daytime sleepiness. The first step in treating Excessive Daytime Sleepiness is always the optimization and maintenance of good sleep hygiene. In OSA-the most dangerous and physiologically disruptive cause of excessive daytime sleepiness-treatment with positive pressure devices (e.g., CPAP) during sleep improves symptoms of daytime sleepiness for most patients.

Typically, a patient is started on a low dose, which is then increased progressively to obtain satisfactory results. Studies have shown that daytime sleepiness can be greatly improved subjectively, but sleep variables are never completely normalized by stimulant treatments. Milder stimulants with low efficacy and potency, such as modafinil or armodafinil, are usually tried first. More effective amphetamine-like stimulants (methylphenidate, D-amphetamine, and methamphetamine) are then used if needed.

There are few drugs approved in the 7MM for the treatment of Excessive Daytime Sleepiness such as Provigil/Modiodal (modafinil), Nuvigil (armodafinil), Sunosi (solriamfetol), Wakix (Pitolisant), Xywav (calcium, magnesium, potassium, and sodium oxybates), and Xyrem (sodium oxybate). The generics of Provigil/Modiodal (modafinil) and Nuvigil (armodafinil) is available in the US market.

Continued in the report…..

Excessive Daytime Sleepiness Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Excessive Daytime Sleepiness, and diagnosed prevalent cases of Excessive Daytime Sleepiness in different disorders in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Key Findings

• In the Epidemiology model of DelveInsight, we have considered five major indications for the estimation of total Excessive Daytime Sleepiness patients population i.e. Parkinson's disease (PD), Narcolepsy, Idiopathic Hypersomnia (IH), Obstructive Sleep Apnea (OSA), and Bipolar Disorder.
• In the 7MM, the total diagnosed prevalent population of Excessive Daytime Sleepiness in 7MM was observed to be 6,857,997 cases in 2021.
• In 2021, the highest cases of Excessive Daytime Sleepiness was estimated from OSA, followed Bipolar Disorder in the United States.
• Assessments as per DelveInsight analysis showed that the US accounted for majority of cases in the 7MM with approximately 3,736,749 diagnosed prevalent cases in 2021.
• In 2021, there were approximately 2,047,802 diagnosed prevalent cases of Excessive Daytime Sleepiness in EU5. Germany accounted highest number of cases.
• In 2021, Japan accounted for approximately 1,073,447 cases of Excessive Daytime Sleepiness. Majority of Excessive Daytime Sleepiness cases were repoted in OSA.

Excessive Daytime Sleepiness Epidemiology

The epidemiology segment also provides the Excessive Daytime Sleepiness epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Excessive Daytime Sleepiness Drug Chapters

The drug chapter segment of the Excessive Daytime Sleepiness report encloses the detailed analysis of Excessive Daytime Sleepiness marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Excessive Daytime Sleepiness clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

Excessive Daytime Sleepiness Marketed Drugs

Wakix/ Ozawade (Pitolisant): Bioprojet Pharma/ Harmony Biosciences

Pitolisant, a histamine H3 receptor (H3R) antagonist, was developed for its awakening effect in the treatment of narcolepsy with or without cataplexy. Approval from the European marketing authorization was obtained for this indication in March 2016 (under the brand name Wakix). A pediatric investigation plan is underway, and studies are being carried out in narcoleptic children.

Products detail in the report…

Sunosi (Solriamfetol): Jazz Pharmaceuticals.

Sunosi is dual-acting dopamine, and norepinephrine reuptake inhibitor (DNRI) is indicated to improve wakefulness in adults living with Excessive Daytime Sleepiness due to narcolepsy or OSA. In 2014, Jazz Pharmaceuticals acquired a license to develop and commercialize Sunosi from Aerial Biopharma. Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to Sunosi, excluding certain jurisdictions in Asia. SK Biopharmaceuticals, the discoverer of the compound, maintains rights in 12 Asian markets, including Korea, China, and Japan. Sunosi has received Orphan Drug designation for narcolepsy in the United States

Products detail in the report…

Excessive Daytime Sleepiness Emerging Drugs

FT218 (Sodium Oxybate): Avadel Pharmaceutical

Avadel's FT218 is an investigational, once-nightly formulation of sodium oxybate using a proprietary micropump technology for extended-release oral suspension in treating Excessive Daytime Sleepiness and cataplexy in patients suffering from narcolepsy. Sodium oxybate is indicated for the treatment of Excessive Daytime Sleepiness and cataplexy in patients with narcolepsy. The currently marketed product, an immediate release (IR) sodium oxybate is required to be taken twice nightly: at bedtime and 2.5-4 h later, thus requiring patients to awaken in the middle of the night. Avadel is currently evaluating the long-term safety and tolerability of FT218 in the open-label RESTORE clinical study, and the NDA is under FDA reviewing procedure.

Products detail in the report…

AXS-12 (Reboxetine): Axsome Therapeutic

AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor under development for the treatment of narcolepsy. It modulates noradrenergic activity to promote wakefulness, maintain muscle tone, and enhance cognition. Reboxetine has an extensive safety record in Europe and in over 40 countries, including the US, where it is approved for the treatment of depression. AXS-12 in narcolepsy is supported by positive preclinical and preliminary clinical results. It significantly reduced narcoleptic episodes in the hypocretin (orexin)-deficient mice and improved daytime sleepiness with reduced cataplexy in patients with narcolepsy in an open-label pilot trial. The drug is presently being evaluated in the Phase III clinical trials for the treatment of narcolepsy.

Products detail in the report…

List to be continued in the report…

Excessive Daytime Sleepiness Market Outlook

The evaluation and management of Excessive Daytime Sleepiness are based on the identification and treatment of underlying conditions (particularly Narcolepsy, Parkinson's disease, Obstructive sleep apnea (OSA), Idiopathic hypersomnia (IH), and Bipolar Disorder, etc.). For all the indications, the mainstay of treatment is supportive care and approved therapies to alleviate the symptoms. Supportive therapies include armodafinil (R-enantiomer of modafinil), amphetamine, methamphetamine, dextroamphetamine, and methylphenidate, etc.

Sleepiness is usually treated using amphetamine-like CNS stimulants (i.e., methylphenidate or modafinil and its R-enantiomer, armodafinil), which are wake-promoting compounds unrelated to amphetamines. More recently, the American Academy of Sleep Medicine (AASM) recommended the use of sodium oxybate, a short-lasting sedative of unknown mechanisms, as the first-line treatment of Excessive Daytime Sleepiness and cataplexy. The most commonly used amphetamine-like compounds are methylphenidate, methamphetamine, D-amphetamine (all schedule II compounds), and mazindol (a schedule IV compound). The clinical use of stimulants in narcolepsy often has been the subject of standards of practice published by AASM.

According to DelveInsight, market of Excessive Daytime Sleepiness in 7MM is expected to change in the study period 2019-2032.

Key Findings

• The therapeutic market of Excessive Daytime Sleepiness in the 7MM was USD 4,946 million in 2021.
• The therapeutic market of Excessive Daytime Sleepiness in the United States was USD 3,399 million in the year 2021.
• The current market of Excessive Daytime Sleepiness is mainly covered by Sunosi, Wakix, Xyrem, Xywav, and others. The market size of Xyrem and Wakix was USD 1,594 million and USD 432 million, respectively in 2021, in the 7MM.
• The market size in the 7MM might increase at a CAGR of 6.77%. An increase in the prevalence of Excessive Daytime Sleepiness, expansion in label of current therapies, and expected launch of emerging treatment, are the primary factors driving the growth of the Excessive Daytime Sleepiness market.
• With the expected launch of upcoming therapies, FT218 (Sodium Oxybate), AXS-12 (Reboxetine), and Xywav (in EU) for Excessive Daytime Sleepiness in Narcolepsy; THN102 for Excessive Daytime Sleepiness in PD, Xywav for Excessive Daytime Sleepiness in IH; Ozawade for Excessive Daytime Sleepiness in OSA, the total market of Excessive Daytime Sleepiness is expected to show a decent change in upcoming years specially for PD, and IH..
• The therapeutic market of Excessive Daytime Sleepiness in Japan was observed to be USD 361 million in the year 2021.

The United States Market Outlook

This section provides the total Excessive Daytime Sleepiness market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total Excessive Daytime Sleepiness market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Excessive Daytime Sleepiness market size and market size by therapies in Japan are provided.

Excessive Daytime Sleepiness Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Excessive Daytime Sleepiness market or expected to get launched in the market during the study period 2019-2032. The analysis covers Excessive Daytime Sleepiness market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Excessive Daytime Sleepiness Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Excessive Daytime Sleepiness emerging therapies.

Reimbursement Scenario in Excessive Daytime Sleepiness

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Excessive Daytime Sleepiness market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Excessive Daytime Sleepiness, explaining its signs and symptoms, causes, classification and currently available therapies.
• Comprehensive insight has been provided into the Excessive Daytime Sleepiness epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Excessive Daytime Sleepiness is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Excessive Daytime Sleepiness market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Excessive Daytime Sleepiness market.

Report Highlights:

• The robust pipeline with novel MOA and oral ROA and increasing prevalence will positively drive the Excessive Daytime Sleepiness market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Excessive Daytime Sleepiness R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition and underlying cause.
• Major players are involved in developing therapies for Excessive Daytime Sleepiness. Launch of emerging therapies will significantly impact the Excessive Daytime Sleepiness market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Excessive Daytime Sleepiness Report Insights

• Patient Population
• Therapeutic Approaches
• Excessive Daytime Sleepiness Pipeline Analysis
• Excessive Daytime Sleepiness Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Excessive Daytime Sleepiness Report Key Strengths

• 11-Years Forecast
• 7MM Coverage
• Excessive Daytime Sleepiness Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Excessive Daytime Sleepiness Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• SWOT analysis

Key Questions

Market Insights:

• What was the Excessive Daytime Sleepiness's market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Excessive Daytime Sleepiness's total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Excessive Daytime Sleepiness market size during the forecast period (2022-2032)?
• At what CAGR, the Excessive Daytime Sleepiness market is expected to grow at the 7MM level during the forecast period (2022-2032)?
• What would be the Excessive Daytime Sleepiness market outlook across the 7MM during the forecast period (2022-2032)?
• What would be the Excessive Daytime Sleepiness market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of Excessive Daytime Sleepiness?
• What is the historical Excessive Daytime Sleepiness patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient population of Excessive Daytime Sleepiness at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Excessive Daytime Sleepiness?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Excessive Daytime Sleepiness during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Excessive Daytime Sleepiness along with the approved therapy?
• What are the current treatment guidelines for the treatment of Excessive Daytime Sleepiness in the US and Europe?
• What are the Excessive Daytime Sleepiness marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Excessive Daytime Sleepiness?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Excessive Daytime Sleepiness?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Excessive Daytime Sleepiness therapies?
• What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Excessive Daytime Sleepiness and their status?
• What are the key designations that have been granted for the emerging therapies for Excessive Daytime Sleepiness?
• What are the 7MM historical and forecasted market of Excessive Daytime Sleepiness?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Excessive Daytime Sleepiness.
• To understand the future market competition in the Excessive Daytime Sleepiness market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Excessive Daytime Sleepiness in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Excessive Daytime Sleepiness market.
• To understand the future market competition in the Excessive Daytime Sleepiness market.

Table of Contents

1 Key Insights

2 Report Introduction

3 Excessive Daytime Sleepiness Market Overview at a Glance

• 3.1 Market Share (%) Distribution of Excessive Daytime Sleepiness in 2019
• 3.2 Market Share (%) Distribution of Excessive Daytime Sleepiness in 2032

4 Excessive Daytime Sleepiness Market: Future Perspective

5 Executive Summary of Excessive Daytime Sleepiness

6 Key Events

7 Excessive Daytime Sleepiness: Disease Background and Overview

• 7.1. Introduction
• 7.2. Causes of Excessive Daytime Sleepiness
• 7.3. Symptoms of Excessive Daytime Sleepiness
• 7.4. Classification
• 7.5. Diagnosis
  • 7.5.1. Diagnostic Algorithm
  • 7.5.2. Diagnosis Guidelines
• 7.6. Treatment and Management of Excessive Daytime Sleepiness
  • 7.6.1. Treatment Algorithm
  • 7.6.2. American Academy of Sleep Medicine Clinical Practice Guideline

8 Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Epidemiology Methodology
• 8.3. Assumptions and Rationale: 7MM
  • 8.3.1. The United States
  • 8.3.2. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
    • 8.3.2.1. Germany
    • 8.3.2.2. France
    • 8.3.2.3. Italy
    • 8.3.2.4. Spain
    • 8.3.2.5. The United Kingdom
  • 8.3.3. Japan
• 8.4. Total Diagnosed Prevalent Population of Excessive Daytime Sleepiness in the 7MM
• 8.5. The United States
  • 8.5.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the US
  • 8.5.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the US
• 8.6. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
  • 8.6.1. Germany
    • 8.6.1.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Germany
    • 8.6.1.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Germany
  • 8.6.2. France
    • 8.6.2.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in France
    • 8.6.2.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in France
  • 8.6.3. Italy
    • 8.6.3.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Italy
    • 8.6.3.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Italy
  • 8.6.4. Spain
    • 8.6.4.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Spain
    • 8.6.4.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Spain
  • 8.6.5. The United Kingdom
    • 8.6.5.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the UK
    • 8.6.5.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the UK
• 8.7. Japan
  • 8.7.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Japan
  • 8.7.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Japan

9 Patient Journey

10 Marketed drugs:

• 10.1. Key Competitors
• 10.2. Wakix/ Ozawade (Pitolisant): Bioprojet Pharma/ Harmony Biosciences
  • 10.2.1. Drug Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Development Activities
  • 10.2.4. Clinical Development
  • 10.2.5. Clinical Trials Information
  • 10.2.6. Safety and Efficacy
  • 10.2.7. Product Profile
• 10.3. Sunosi (Solriamfetol): Jazz Pharmaceuticals
  • 10.3.1. Drug Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Development Activities
  • 10.3.4. Clinical Development
  • 10.3.5. Clinical Trials Information
  • 10.3.6. Safety and Efficacy
  • 10.3.7. Product Profile
• 10.4. Xyrem (Sodium oxybate): Jazz Pharmaceuticals
  • 10.4.1. Drug Description
  • 10.4.2. Regulatory Milestones
  • 10.4.3. Other Development Activities
  • 10.4.4. Clinical Development
  • 10.4.5. Clinical Trials Information
  • 10.4.6. Safety and Efficacy
  • 10.4.7. Product Profile
• 10.5. Xywav (calcium, magnesium, potassium, and sodium oxybates): Jazz Pharmaceuticals
  • 10.5.1. Drug Description
  • 10.5.2. Regulatory Milestones
  • 10.5.3. Other Development Activities
  • 10.5.4. Clinical Development
  • 10.5.5. Clinical Trials Information
  • 10.5.6. Safety and Efficacy
  • 10.5.7. Product Profile

11 Emerging Drugs

• 11.1. Key Cross Competition
• 11.2. FT218 (Sodium Oxybate): Avadel Pharmaceutical
  • 11.2.1. Product Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Development
  • 11.2.4. Clinical Trials Information
  • 11.2.5. Safety and Efficacy
  • 11.2.6. Product Profile
  • 11.2.7. Analysts' Views
• 11.3. AXS-12 (Reboxetine): Axsome Therapeutic
  • 11.3.1. Product Description
  • 11.3.2. Other Development Activities
  • 11.3.3. Clinical Development
  • 11.3.4. Clinical Trials Information
  • 11.3.5. Safety and Efficacy
  • 11.3.6. Product Profile
  • 11.3.7. Analysts' Views
• 11.4. THN102 (Flecainide and Modafinil): Theranexus
  • 11.4.1. Product Description
  • 11.4.2. Other Developmental Activities
  • 11.4.3. Clinical Development
  • 11.4.4. Clinical Trials Information
  • 11.4.5. Safety and Efficacy
  • 11.4.6. Product Profile
  • 11.4.7. Analysts' Views
• 11.5. Samelisant (SUVN-G3031): Suven Life Sciences
  • 11.5.1. Product Description
  • 11.5.2. Other Developmental Activities
  • 11.5.3. Clinical Development
  • 11.5.4. Clinical Trials Information
  • 11.5.5. Safety and Efficacy
  • 11.5.6. Product Profile
• 11.6. Quilience (Mazindol Extended-release/NLS-2): NLS Pharma Ltd
  • 11.6.1. Product Description
  • 11.6.2. Other Developmental Activities
  • 11.6.3. Clinical Development
  • 11.6.4. Clinical Trials Information
  • 11.6.5. Product Profile
  • 11.6.6. Analysts' Views
• 11.7. XW10172: XWPharma
  • 11.7.1. Product Description
  • 11.7.2. Clinical Development
  • 11.7.3. Clinical Trials Information
  • 11.7.4. Safety and Efficacy
  • 11.7.5. Product Profile
  • 11.7.6. Analysts' Views
• 11.8. TAK-994: Takeda Pharmaceutical
  • 11.8.1. Product Description
  • 11.8.2. Other Developmental Activities
  • 11.8.3. Clinical Development
  • 11.8.4. Clinical Trials Information
  • 11.8.5. Product Profile
  • 11.8.6. Analysts' Views

12 Excessive Daytime Sleepiness: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Methodology
• 12.3. Market Size of Excessive Daytime Sleepiness in the 7MM
• 12.4. Market Size of Excessive Daytime Sleepiness by Therapies in the 7MM
• 12.5. Potential of Current and Emerging Therapies
• 12.6. Key Market Forecast Assumptions
• 12.7. Attribute Analysis
• 12.8. Market Outlook
• 12.9. Market Size of Excessive Daytime Sleepiness in the United States
  • 12.9.1. Total Market Size of Excessive Daytime Sleepiness
  • 12.9.2. Market Size of Excessive Daytime Sleepiness by Therapies
• 12.10. Market Size of Excessive Daytime Sleepiness in the EU-5
  • 12.10.1. Germany
    • 12.10.1.1. Total Market Size of Excessive Daytime Sleepiness
    • 12.10.1.2. Market Size of Excessive Daytime Sleepiness by Therapies
  • 12.10.2. France
    • 12.10.2.1. Total Market Size of Excessive Daytime Sleepiness
    • 12.10.2.2. Market Size of Excessive Daytime Sleepiness by Therapies
  • 12.10.3. Italy
    • 12.10.3.1. Total Market Size of Excessive Daytime Sleepiness
    • 12.10.3.2. Market Size of Excessive Daytime Sleepiness by Therapies
  • 12.10.4. Spain
    • 12.10.4.1. Total Market Size of Excessive Daytime Sleepiness
    • 12.10.4.2. Market Size of Excessive Daytime Sleepiness by Therapies
  • 12.10.5. The United Kingdom
    • 12.10.5.1. Total Market Size of Excessive Daytime Sleepiness
    • 12.10.5.2. Market Size of Excessive Daytime Sleepiness by Therapies
• 12.11. Market Size of Excessive Daytime Sleepiness in Japan
  • 12.11.1. Total Market Size of Excessive Daytime Sleepiness
  • 12.11.2. Market Size of Excessive Daytime Sleepiness by Therapies

13 Key Opinion Leaders' Views

14 Market Drivers

15 Market Barriers

16 SWOT Analysis

17 Unmet Needs

18 Reimbursement and Market Access

19 Appendix

• 19.1. Bibliography
• 19.2. Report Methodology

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight